Extract healthy single cells from solid tissues with a new automation solution. We provide reliable single-cell analysis results. *Video available.
By combining a novel and gentle massage-style process with customizable solutions for temperature and time, we achieve the extraction of single cells from solid tissues such as tumors with minimal damage and a high survival rate. This can be utilized in single-cell RNA sequencing and various omics applications (genomics, proteomics, metabolomics), as well as flow cytometry. If you are struggling with noise after sequence analysis, the number of detected cells, or the number of genes, this is a must-see! *For more details, please contact us or download the PDF materials. *If you would like a demo, please get in touch.
Inquire About This Product
basic information
【Features of the Device】 ● No need for tissue cutting work, reducing the burden on operators ● Automatic dispersion completes in as little as 10 minutes, providing significant time savings ● Gentle digestion process optimizes cell viability and reduces debris ● Dispersion processing while retaining relative cells to the original sample ● High reproducibility achieved through standardization and automation of sample preparation ● The functionality of the VIA Freeze speed-controlled freezer allows customization of temperature (e.g., 4°C) and time, enabling reliable results based on sample type and size ● Use of a closed-system single-use pouch minimizes cell loss and contamination, allowing for parallel processing of up to three samples
Price range
Delivery Time
Applications/Examples of results
■ Single-cell RNA-seq ■ Single-nucleus RNA-seq ■ Flow cytometry For more details, please contact us or download the catalog.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.
